Journal Papers, Abstracts, and Commentaries
| |
Population pharmacokinetic modeling and simulation of amprenavir
following fosamprenavir/ritonavir administration for dose optimization
in HIV infected pediatric patients.
Barbour AM, Gibiansky L, Wire MB.
J Clin Pharmacol.
2014 Feb;54(2):206-14
Abstract
Post-licensing safety of fosamprenavir in HIV-infected
children in Europe.
Judd A, Duong T, Galli L,
et al
Pharmacoepidemiol Drug Saf.
2014 Mar;23(3):321-5.
Abstract
Pharmacokinetics and 48 Week Safety and Antiviral Activity of
Fosamprenavir-Containing Regimens in HIV-Infected 2 to 18 Year-Old Children.
Fortuny C, Duiculescu D, Cheng K, et al
Pediatr Infect Dis J. 2013 Jun 27
Abstract
Pharmacokinetics, Safety and Antiviral Activity of
Fosamprenavir/Ritonavir-Containing.
Cotton M, Cassim H, Pavía-Ruz N, et al
Pediatr Infect Dis J.
2013 Jun 27.
Abstract
Long-Term Efficacy and Safety of Fosamprenavir in Human Immunodeficiency
Virus-Infected Pediatric Patients.
Palladino C, Briz V, Policarpo SN, et al
Pediatr Infect Dis J. 2010
Feb 12
Abstract |
|
|
|
Conference Reports, Abstracts and Posters
| |
POSTER
Use and safety of fosamprenavir in HIV-infected children in the European
Union: an ongoing
post-marketing surveillance study
A. Judd, L. E, L. Galli, T. Goetghebuer .et al
(6th IAS Conference)
Poster
Abstract |
|
|
New
and Noteworthy
Journal
Data
Guidelines
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
